Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 5/20 | 0.76 |
| ▸ | CTSK | P43235 | 5/20 | 0.76 |
| ▸ | ACE | P12821 | 4/20 | 0.56 |
| ▸ | MME | P08473 | 2/20 | 0.56 |
| ▸ | CPA1 | P15085 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.56 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | CTSL | P07711 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL613640 | 1.00 | CTSS (0.76) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL29401990 | 1.00 | CTSS (0.76) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL4122289 | 1.00 | CTSS (0.76) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL17137918 | 0.95 | CTSS (0.77) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL17137921 | 0.95 | CTSS (0.77) | CTSSCTSKACEMMECPA1 | |
| Dipentylamine SCHEMBL9536578 | 0.89 | CTSK (0.63) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL345085 | 0.89 | CTSK (0.65) | CTSSCTSKACEPTPN1CYP3A4 | |
| SCHEMBL7288479 | 0.89 | CTSK (0.65) | CTSSCTSKACEPTPN1CYP3A4 | |
| SCHEMBL8662603 | 0.89 | CTSS (0.62) | CTSSCTSKACEMMECPA1 | |
| SCHEMBL8554176 | 0.89 | CTSS (0.74) | CTSSCTSKACEMMECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113260365-A | Novel compound and pharmaceutical composition for enhancing anticancer activity comprising the same | 治愈医药社株式会社 | 2021-08-13 | — | — | CN | disclosed |
| CN-105189524-B | The synthetic method of optical activity alpha-amino acid | 浜理药品工业株式会社 | 2019-07-19 | — | — | CN | disclosed |
| US-10242871-B2 | Resist underlayer film-forming composition including a compound having an amino group protected with a tert-butoxycarbonyl group | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2019-03-26 | — | — | US | disclosed |
| US-20170250079-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170250079-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-06-08 | — | — | US | disclosed |
| US-9604994-B2 | Thienopyrimidine inhibitors of atypical protein kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2017-03-28 | — | — | US | disclosed |
| EP-3048106-A1 | THIENOPYRIMIDINE AS INHIBITORS OF ATYPICAL PROTEIN KINASE C | Cancer Research Technology Limited (GB) | 2016-07-27 | — | — | EP | disclosed |
| EP-2782917-B1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | CANCER REC TECH LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2014-10-30 | — | — | US | disclosed |
| EP-0480969-A4 | AMINO ACID ANALOG CCK ANTAGONISTS | — | 1993-01-07 | — | — | EP | disclosed |
| EP-0480969-A1 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1992-04-22 | — | — | EP | disclosed |
| WO-1991000725-A2 | AMINO ACID ANALOG CCK ANTAGONISTS | ABBOTT LABORATORIES (US) | 1991-01-24 | — | — | WO | disclosed |
| EP-0049628-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH, USEFUL AS LHRH ANTAGONISTS, METHODS OF MAKING THEM, AND THEIR PHARMACEUTICAL USES | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0021234-B1 | NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OF LUTEINIZING HORMONE RELEASING HORMONE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4419347-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4341767-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0049628-A2 | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| EP-0021234-A1 | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4234571-A | CONTRACEPTIVES, ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323435-A1 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C | PRKCQ, PRKDC, PRKACA | CTSS 4492/4885CTSK 1686/4885ACE 2290/4885 |
| US-20170158706-A1 | THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C | PRKCQ, PRKDC, PRKACA | CTSS 4492/4885CTSK 1686/4885ACE 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.